Research Shows Promise of Technology Used by Turn Biotechnologies to Develop Therapies for Age-Related Diseases
Mar 24, 2020
MOUNTAIN VIEW, Calif., March 25, 2020 /PRNewswire/ -- A study published in the respected Nature Communications journal highlights the promise of technology being developed by Turn Biotechnologies to treat age-related health conditions.
The study by researchers at the Stanford University School of Medicine found that old human cells can be induced into a more youthful and vigorous state when they are exposed to a rejuvenating treatment that triggers the limited expression of a group of proteins known as Yamanaka factors, which are important to embryonic development.
What distinguishes the study is that it reports the first-time researchers have used Yamanaka factors to undo many of the effects of aging on cells without eliminating their DNA of the molecular tags that differentiate, for example, skin cells from heart muscle cells. Normally, Yamanaka factors transform adult cells into induced pluripotent stem cells, which can become nearly any type of cell in the body.
"We've wondered if it might be possible to simply rewind the aging clock without inducing pluripotency," said Vittorio Sebastiano, assistant professor at Stanford University and senior author of the Nature Communications article. "Now we've found that tightly controlling the exposure to these proteins can promote rejuvenation in multiple human cell types, including stem cells. This has profound implications for regeneration and restoration of cell functionality of aged tissues."
The technology described in the study is being used by Turn in the development of therapies that will induce the body to repair age-related diseases and conditions.
Sebastiano, a Turn co-founder who remains on the faculty at Stanford, said the research findings offer promise of breakthrough treatments for diseases that are currently untreatable.
"We are hopeful that we may one day have the opportunity to reboot entire tissues," he said.
ABOUT TURN BIOTECHNOLOGIES
Turn is a development-stage company focused on repairing tissue at the cellular level. Our proprietary mRNA technology combats the effects of aging in the epigenome, thus restoring optimal gene expression and enabling cells to function as vigorously as when they were younger. Our technology provides a platform from which to attack a variety of diseases related to age. We are currently researching applications in dermatological, respiratory and osteoarthritic conditions. For more information, see www.turn.bio.
FOR MORE INFORMATION, CONTACT:
Jim Martinez, rightstorygroup
[email protected] or (312) 543-9026
SOURCE Turn Biotechnologies
Related Links
More News
This city slicker took a job in Darwin. What happened next surprised her
Long-time city dweller Emma Jane Edwards decided to move on whim 18 months ago.
They transformed the Espy. Now they want to revive a vacant Fitzroy pub
Five mates who launched a pub empire in their 20s have purchased a historic pub in Brunswick Street.
Why your closest friends probably won’t help you find a job
The surprising reality is that your next career move will probably emerge from the very edge of your orbit.
My accent is unremarkable. But it has almost certainly helped me
There’s a type of bias holding us back, economically and socially. Here’s how the way we speak might be shaping how people perceive us.
‘Hard to say there won’t be job cuts’, freshly arrived ABC news chief declares
In his first big day greeting staff, Simon Robinson did not confirm there would be job cuts, but pointedly avoided ruling out redundancies.
Qantas ground staff set to strike over ‘Joyce-era’ bargaining agreements
The 600 workers poised to go on strike are the last remaining Qantas ground workers, after 1800 of their colleagues were illegally sacked during the COVID pandemic.
‘They’re wolves’: Coles keeps milk prices higher despite axing farmer support
The supermarket giant started charging customers more when war broke out in the Middle East to support farmers. Now it and a Woolworths supplier have ended subsidies.
ASX gains as oil prices, bond yields ease; Big four banks advance
The Australian sharemarket has risen for the second day in a row after the Federal Reserve’s first interest rate rise in three years and a drop in oil prices.
Why AI hasn’t taken your job yet
The predicted AI job apocalypse hasn’t landed yet. But the industry is more concerned about the bigger problem of human extinction.
KPMG consultant admits to ‘gaps’ in its whistleblower report
A comprehensive report on KPMG’s whistleblower failings has come up short, as key staff weren’t interviewed and there were no records of crucial meetings.
Dalaroo survey lights up deep WA copper-nickel-PGE targets
Dalaroo Metals has homed in on priority drill targets at its Watheroo copper-nickel-PGE project in WA, after a new IP survey confirmed prior exploration indicators.
Why you should be wary when your boss asks for feedback
The idea of the “360-degree feedback” has always struck me as worthy in theory but highly dubious in practice.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.